Overview

Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Treatments:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Drospirenone
Drospirenone and ethinyl estradiol combination
Ethinyl Estradiol
Criteria
Inclusion Criteria:

- Female requiring contraceptives.

- Aged 18 to 35 if a non-smoker, aged 18 to 30 if a smoker.

- Regular menstrual cycle (defined as duration of 28 +/- 5 days).

Exclusion Criteria:

- No Contraindication for OC use